NCT03595800 (HaploMUD-RIC) is a Phase 3 clinical trial of Hematopoietic stem cells transplantation in Acute Leukemia, sponsored by Institut Paoli-Calmettes.

Who is sponsoring NCT03595800?

NCT03595800 is sponsored by Institut Paoli-Calmettes.

What drugs are being tested in NCT03595800?

Interventions in NCT03595800: Hematopoietic stem cells transplantation.

What condition does NCT03595800 study?

NCT03595800 studies Acute Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma.

Is NCT03595800 still recruiting?

NCT03595800 is currently completed. Last updated 4 October 2024.

Last reviewed 2024-10-04 · How we verify

NCT03595800: HaploMUD-RIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen

Completed Phase 3 Last updated 4 October 2024

What this trial tests

Phase 3 trial testing Hematopoietic stem cells transplantation in Acute Leukemia in 9 participants. Completed in 12 March 2021.

Timeline

19 September 2017

Primary endpoint
2 February 2021

12 March 2021

Quick facts

Lead sponsor	Institut Paoli-Calmettes
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	19 September 2017
Primary completion	2 February 2021
Estimated completion	12 March 2021
Sites	1 location across France

Drugs / interventions tested

Hematopoietic stem cells transplantation

Conditions studied

Acute Leukemia — all drugs for Acute Leukemia →
Non Hodgkin Lymphoma — all drugs for Non Hodgkin Lymphoma →
Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Institut Paoli-Calmettes — full company profile →

Who can join

Adults 18 to 55, any sex, with Acute Leukemia or Non Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is an extension to younger patients of the currently ongoing national, multicenter, open-label, randomized phase III HAPLOMUDELDERLY which evaluates elderly patients with hematological malignancies, justifying an allo-HSCT from an alternative donor when a MRD has not been identified. It will extend the investigation of these two modalities of allo-HSCT to younger patients which are eligible to RIC.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Leukemia

Currently open trials in the same condition.

NCT07270770 — BY002 IIT Study in R/R Acute Leukemia · Phase 1 · recruiting
NCT07356154 — A Study of Revumenib and Mezigdomide in People With Leukemia · Phase 1, PHASE2 · recruiting
NCT07362095 — Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) · Phase 1, PHASE2 · recruiting
NCT07101497 — Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia · Phase 2 · recruiting
NCT06984536 — Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT · Phase 2 · recruiting

Other Institut Paoli-Calmettes trials

Trials by the same sponsor.

NCT07461142 — Reduction of Hematologic Toxicity in Locally Advanced Cervical Cancers · NA · not yet recruiting
NCT06557421 — De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients · Phase 2 · recruiting
NCT06046794 — Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients · NA · recruiting
NCT06055621 — Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE · Phase 2 · recruiting
NCT05986071 — I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03595800 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Paoli-Calmettes
Last refreshed: 4 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03595800.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing